- $5.10m
- -$4.98m
- $1.20m
Advisory: Alert from FN Media Group wrongly tagged to multiple companies withdrawn
Brief: Longeveron Announces Exercise Of Warrants For $4.4 Million Gross Proceeds
Brief: Longeveron® Announces Completion Of Successful Investigator Meeting For On-Going Phase 2B Clinical Trial Evaluating Lomecel-B™ As A Potential Treatment For HLHS, A Rare Pediatric Cardiac Disease
Brief: Longeveron Raises $11.4 Mln In Gross Proceeds From Warrant Exercise Offering, Public Offering
U.S. STOCKS ON THE MOVE-Longeveron, Novavax, Telsa
Brief: Longeveron Announces Closing Of $5.2 Million Public Offering
Brief: Longeveron Announces 1-For-10 Reverse Stock Split
Brief: Longeveron Received Notice From Nasdaq
Brief: Longeveron Receives Notice Of United States Patent Allowance For Technology Behind Its Product Lomecel-B
Brief: Longeveron Closes $2.36 mln Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Longeveron Announces $2.36 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
U.S. STOCKS ON THE MOVE-Coinbase Global, Spirit AeroSystems, Crown Castle
U.S. STOCKS ON THE MOVE-Toro, TRACON Pharma, Fulton Financial
U.S. STOCKS ON THE MOVE-Passage Bio, Discover Financial, Alphabet
Longeveron rises on positive results from Alzheimer's treatment trial
Brief: Longeveron Announces Additional Positive Clinical Data And Imaging Biomarker Results From The Clear Mind Phase 2A Trial Of Lomecel-B™
Advisory: Incorrect alert on Barclays Bank share resale withdrawn
Brief: Longeveron Files For Resale Of Up To 5.02 Million Shares Of Class A Common Stock By The Selling Stockholders - SEC Filing
Brief: Long-Term Survival Data From Longeveron's Elpis 1 Trial Presented At The 2023 Scientific Sessions Of The American Heart Association